75.07±13.8, WOMAC pain score was 16.1±3.6. Eighty-two patients of 161 (50.9%) had neuropathic pain. When diabetics were excluded (n=58), the proportion of patients with neuropathic pain reduced to 45.6%. The most frequently described pain characteristic was sensation of electric shock (58.4%). Mean total WOMAC and physical function subscale was significantly higher in neuropathic pain group when compared to no neuropathic pain group (DN4 score 3 or less), 77.5±11.5 versus 72.6±15.5, p=0.024; and 54.3±8.8 and 49.8±12.6 respectively, p=0.008 Conclusions: Neuropathic pain was seen in up to 50% patients with knee OA. Centrally acting drugs like tricyclic anti-depressants or duloxetine can be used to improve pain and physical function in patients of knee OA with neuropathic pain. Background: Midkine is a heparin-binding growth factor that plays an important role in mesoderm remodeling as in chondrogenesis and adipocyte formation. There is an increased expression of midkine in damaged tissues and it is believed to have functional antagonism, as it helps in tissue repair and survival while, on the other hand it can enhance inflammatory reactions resulting in more tissue injury [1] . Objectives: This study aimed to determine serum and synovial fluid (SF) levels of midkine in patients with primary knee osteoarthritis (KOA) and to examine the relationship between these levels with the clinical and functional parameters as well as radiological progression of KOA. Methods: We measured midkne in the serum (n=52) and SF samples (n=23) from 52 KOA patients as well as in the serum from 20 healthy control (n=20). In the patients, numerical rating scale of pain (NRSP), body mass index (BMI) and The Western Ontario Mc Master scale (WOMAC) were recorded. Graded plain radiographs using Thomas score, and musculoskeletal ultrasound examination (MSUS) of both knees were performed at baseline and after 24 months to assess radiological progression [2, 3] . Radiological progression was considered if there is an increase in the Thomas grading score or MSUS transition to a higher grade at the 24 months follow up period compared to baseline evaluation. Results: Serum and SF midkine levels were significantly increased in KOA patients (mean ± SD 80.79±31.8 pg/mL and 216.31±94.93 pg/mL respectively) compared to serum level in the healthy controls (mean ± SD 65.6±14.76 pg/mL),p<0.05 and p<0.001 respectively. In KOA patients, the serum and SF concentrations of midkine significantly correlated with the baseline thickness of the cartilage on the medial condyle (r= −0.41 and -0.52 respectively, p<0.05) but not on the lateral condyle of the femur (r=0.12 and 0.15 respectively, p>0.05). Patients with elevated serum and SF midkine (defined as midkine level more than the mean plus 2 standard deviation of healthy controls's level) had a twofold increased risk of radiological progression with MSUS (age, sex and BMI adjusted RR 2.4 and 2.6, 95% CI respectively).With elevated serum and SF midkine levels, there was no increased risk of radiological progression detected with plain radiography in KOA Patients (age, sex and BMI adjusted RR 1.3 and 1.6, 95% CI respectively). Conclusions: Osteoarthritis patients have significantly elevated serum and synovial levels of midkine that were obviously associated with radiological progression on MSUS suggesting that it could be a useful marker to reflect OA severity and implies a possible role in the pathogenesis of OA. Background: Knee osteoarthritis (OA) is characterized by pain, disability and joint deformity due to degradation of articular cartilage and bone remodeling. The Wnt signaling pathway has a role in these cellular processes, and it is also linked to inflammation. SM04690, a small molecule Wnt pathway inhibitor, is in development for the treatment of knee OA as a potential disease modifying drug. A phase 2, multicenter, 52-week, randomized controlled trial of a single intra-articular (IA) injection of SM04690 is ongoing in subjects with moderate to severe knee OA. Clinical results from an interim analysis are reported. were enrolled. SM04690 appeared well tolerated. In the ITT population clinically meaningful improvements in all clinical outcomes compared to baseline were seen for all groups and placebo at weeks 13 and 26 (Table) . Moreover, clinically meaningful improvements in clinical outcomes were also seen in multiple groups over several outcomes at various time points compared to placebo. In the unilateral knee OA subgroup, PTGA (0.03 mg) and MDGA (0.07 mg) were significantly improved compared to placebo. In the WPI≤4 subgroup, WOMAC Pain (0.07 mg), PTGA (0.03 mg) and MDGA (0.07 mg) were significantly improved compared to placebo.
Conclusions:
In this phase 2 interim analysis, the ITT population (SM04690 and placebo groups) demonstrated clinically relevant improvements in clinical outcomes at weeks 13 and 26 compared to baseline. In two subgroups, consistent
